Baird Reiterates a 'Neutral' on Alexion Pharmaceuticals (ALXN); Regulatory Two-Fer; aHUS Indication Cleared in US/EU

Baird reiterates a 'Neutral' on Alexion Pharmaceuticals (NASDAQ: ALXN) new price target of $65.00.

Baird analyst says, "Incrementally positive after two regulatory updates this morning for Soliris' aHUS indication - FDA approval and CHMP recommendation. Both events expected, but both came slightly early. However, with our Soliris revenue estimates already above consensus, combined with customary launch reimbursement and logistical delays, we are keeping our estimates as-is. Remain on the sidelines for now, but on the lookout for any pullback as an opportunity to get more involved."

For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $63.37 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy